New Zealand markets closed

Bayer Aktiengesellschaft (BAYRY)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
7.46-0.01 (-0.13%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.47
Open7.42
Bid7.46 x 40000
Ask7.47 x 40000
Day's range7.40 - 7.47
52-week range6.82 - 14.70
Volume31,392
Avg. volume1,128,920
Market cap29.316B
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-0.86
Earnings date06 Aug 2024
Forward dividend & yield0.03 (0.39%)
Ex-dividend date29 Apr 2024
1y target est22.19
  • Associated Press Finance

    Monsanto agrees to $160 million settlement with Seattle over pollution in the Duwamish River

    Ending an eight-year legal battle, chemical giant Monsanto has agreed to a $160-million settlement with Seattle for its part in polluting a river that runs through the heart of the city with toxins that posed a threat to humans, fish and wildlife, the city attorney's office said Thursday. “We all play a role in protecting our environment and I am glad that Monsanto will contribute to this important environmental cleanup," City Attorney Ann Davison said in a news release. It's the largest single-city settlement Monsanto has paid, she said.

  • Reuters

    Bayer's Monsanto to pay $160 million to resolve Seattle's PCB contamination lawsuit

    Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs. In a statement, Monsanto said it will pay $35 million for PCB remediation, and $125 million to address other Seattle claims. Seattle accused Monsanto of creating a public nuisance by selling polychlorinated biphenyls for commercial use from 1935 to 1977 despite knowing they polluted the environment, harming people and wildlife.

  • Zacks

    Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study

    Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.